AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN

Alcohol and Drug Abuse ALC

H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.

Contacted: Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); White House Office; Food & Drug Administration (FDA); Defense, Dept of (DOD); SENATE; HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC)

Bills named: H.R. 6 (115th)

Disaster Planning/Emergencies DIS

commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)

Contacted: SENATE; Food & Drug Administration (FDA); Defense, Dept of (DOD); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); Centers For Disease Control & Prevention (CDC); White House Office; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 6378 (115th)

Health Issues HCR

regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.

Contacted: Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); Defense, Dept of (DOD); Office of Management & Budget (OMB); White House Office

Bills named: H.R. 1625 (115th), H.R. 6378 (115th), H.R. 6 (115th), H.R. 6157 (115th)

Medicare/Medicaid MMM

reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services

Contacted: Office of Management & Budget (OMB); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD); SENATE; White House Office; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Bills named: H.R. 1625 (115th)

Budget/Appropriations BUD

regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157)

Contacted: Defense, Dept of (DOD); SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); White House Office

Bills named: H.R. 6157 (115th), H.R. 1625 (115th)

Medical/Disease Research/Clinical Labs MED

regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.

Contacted: Defense, Dept of (DOD); Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Office of Management & Budget (OMB); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; White House Office

Bills named: H.R. 6378 (115th), H.R. 6157 (115th), H.R. 1625 (115th), H.R. 6 (115th)

Law Enforcement/Crime/Criminal Justice LAW

H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion; application of anti-kickback laws to clinical laboratories

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Office of Management & Budget (OMB); Defense, Dept of (DOD); SENATE; Centers For Disease Control & Prevention (CDC); White House Office; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 6 (115th)